Omniome
AcquiredSan Diego, US · Founded 2013 · Delaware corporation · 1 known investors
Find your way into Omniome
Acquired by Pacific Biosciences of California, Inc. (PacBio) September 2021 · $800M (~$600M upfront (cash and stock) plus up to $200M in milestone payments, total ~$800M) · source ↗
Omniome was a San Diego biotech that developed Sequencing by Binding (SBB), a proprietary short-read DNA sequencing chemistry aimed at higher accuracy genomic analysis. Its technology became the basis for PacBio's Onso sequencing instrument.
Founders & leadership
DS
David S. MullarkeyExecutive
AO
Arnold OliphantinExecutive
KS
Ken Song, M.D., Ph.D.Executive
KP
Kelly PerezExecutive
JM
John Murphy, Ph.D.Executive
MY
Millard Y ChanChief Operating Officer, Secretary and Director
KV
Kandaswamy VijayanExecutive
Board
BN
Boris Nikolic, M.D.Board director
MY
Michael YiBoard director
KK
Kim Kamdar, Ph.D.Board director
DC
David CruikshankBoard director
DZ
Dan ZabrowskiBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$100.2M disclosed across 3 rounds · 2014–2019
▶$60MraisedDec 2019 · 2 investors · BiotechnologyRule 506(b)
▶$60MraisedDec 2019 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dan ZabrowskiDirector
- Kim Kamdar, Ph.D.Director
- David S. MullarkeyExecutive Officer, Director
- Ken Song, M.D., Ph.D.Executive Officer, Director
- Kelly PerezExecutive Officer
- Arnold OliphantExecutive Officer
- David CruikshankDirector
- Michael YiDirector
- Catherine LeeExecutive Officer
- Offering amount
- $60M
- Amount sold
- $60M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40MraisedFeb 2019 · 9 investors · BiotechnologyRule 506(b)
▶$40MraisedFeb 2019 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David S. MullarkeyExecutive Officer, Director
- Arnold OliphantExecutive Officer
- Boris Nikolic, M.D.Director
- Ken Song, M.D., Ph.D.Executive Officer, Director
- Michael YiDirector
- Kelly PerezExecutive Officer
- Kim Kamdar, Ph.D.Director
- Dan ZabrowskiDirector
- John Murphy, Ph.D.Executive Officer
- David CruikshankDirector
- Offering amount
- $40M
- Amount sold
- $40M
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$225KraisedMay 2014 · 7 investors · BiotechnologyRule 506(b)
▶$225KraisedMay 2014 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Millard Y ChanExecutive Officer, Director
- Kandaswamy VijayanExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $225K
- Minimum investment
- $25K
- First sale
- May 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Omniome do?
- Omniome was a San Diego biotech that developed Sequencing by Binding (SBB), a proprietary short-read DNA sequencing chemistry aimed at higher accuracy genomic analysis. Its technology became the basis for PacBio's Onso sequencing instrument.
- Who are Omniome's investors?
- Omniome's investors include DCVC (Data Collective).
- How much funding has Omniome raised?
- Omniome has disclosed $100.2M raised across 3 rounds.
- Where is Omniome headquartered?
- Omniome is headquartered in San Diego, US.